The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.
 
Hedy L. Kindler
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Bayer; Celgene; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; MedImmune; Merck; Plexxikon; Verastem
Research Funding - AB Science; Aduro Biotech; Astellas Pharma; AstraZeneca; Bayer; Celgene; GlaxoSmithKline; Incyte; MedImmune; Merck; Verastem
 
Arnaud Scherpereel
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MedImmune; Roche
 
Luana Calabrò
Research Funding - AstraZeneca/MedImmune (Inst)
 
Joachim Aerts
Stock and Other Ownership Interests - Amphera
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Roche
Speakers' Bureau - AstraZeneca
Patents, Royalties, Other Intellectual Property - Amphera BV
Travel, Accommodations, Expenses - MSD; Verastem
 
Susana Cedres Perez
No Relationships to Disclose
 
Alessandra Bearz
No Relationships to Disclose
 
Kristiaan Nackaerts
Consulting or Advisory Role - Amgen; Lilly; Pfizer
Research Funding - Amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Novartis (Inst); Takeda (Inst)
Expert Testimony - Pfizer
 
Dean Anthony Fennell
Honoraria - Aduro Biotech; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Lilly; Pierre Fabre; Synta; Verastem
Consulting or Advisory Role - Aduro Biotech; Bayer; Boehringer Ingelheim; Clovis Oncology; Lilly; Pierre Fabre; Synta; Verastem
Speakers' Bureau - Bristol-Myers Squibb; Lilly
Research Funding - Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Aduro Biotech; Bayer; Synta
 
Dariusz Kowalski
No Relationships to Disclose
 
Anne S. Tsao
Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Genentech/Roche; Imedex; Lilly; MedImmune; Novartis
Research Funding - Genentech/Roche (Inst); MedImmune (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Novartis
 
Paul Taylor
Travel, Accommodations, Expenses - Amgen; Pierre Fabre
Other Relationship - Amgen
 
Federica Grosso
No Relationships to Disclose
 
Scott Joseph Antonia
Stock and Other Ownership Interests - Cellular Biomedicine Group
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck
 
Anna K. Nowak
No Relationships to Disclose
 
Ramy A. Ibrahim
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Maria Taboada
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Martina Puglisi
Employment - AstraZeneca
 
Paul K. Stockman
Employment - AstraZeneca
Leadership - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Michele Maio
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme
Research Funding - Astex Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb (Inst); MedImmune